Rectal Adenocarcinoma clinical trials
19 active trials name this condition. Describe your situation to see which ones look like a fit.
Refine by biomarker
By location
- A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
- A Study of Botensilimab and Balstilimab for Rectal Adenocarcinoma
- Trial Utilizing Metronidazole to Optimize the Microbiome of Rectal Adenocarcinoma Undergoing Neoadjuvant Therapy
- FOLFOX, Botensilimab, and Balstilimab for the Treatment of Localized Rectal Cancer Before Surgery
- MRI-Guided Adaptive Radiation Therapy for Organ Preservation in Rectal Cancer
- A Study of Tucatinib and Trastuzumab in People With Rectal Cancer
- Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- Tislelizumab in People With Colorectal Cancer
- Papaverine in Combination With Radiation Therapy for the Treatment of Locally Advanced Rectal Cancer, DINOMITE Trial
- Active Surveillance and Chemotherapy Before Surgery in Treating Participants With Stage II-III Rectal Cancer
- Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors
- Evaluating Novel Therapies in ctDNA Positive GI Cancers
- Family Communications After Genetic Testing
- Establishing a ctDNA Biomarker to Improve Organ Preserving Strategies in Patients With Rectal Cancer
- Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
- ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps
- ctDNA-Informed Management of Early-Stage Rectal Cancer
- A Study of Trastuzumab Deruxtecan (T-DXd) and Cetuximab in People With Colorectal Cancer
Guides for people searching for a trial
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that list “Rectal Adenocarcinoma” as a condition. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.